High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory hodgkin's disease : Analysis of the Stanford University results and prognostic indices

• Published in: Blood Vol. 89; no. 3; pp. 801 - 813
• Main Authors: HORNING, S. J, CHAO, N. J, NEGRIN, R. S, HOPPE, R. T, LONG, G. D, HU, W. W, WONG, R. M, BROWN, B. W, BLUME, K. G
• Format: Journal Article
• Language: English
• Published: Washington, DC The Americain Society of Hematology 01.02.1997
• Subjects: Adolescent; Adult; Antineoplastic agents; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Biological and medical sciences; Combined treatments (chemotherapy of immunotherapy associated with an other treatment); Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Hodgkin Disease - drug therapy; Hodgkin Disease - surgery; Humans; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Prognosis; Prospective Studies; Recurrence; Regression Analysis; Survival Analysis; Transplantation, Autologous; Antineoplastic agent; Relapse; Transfusion; Prognosis; Nitrosoureas; Stem cell; Hematopoietic cell; Blood; Autograft; Isomerases; Lymphoproliferative syndrome; Lomustine; Antimitotic; Negative therapeutic reaction; DNA topoisomerase (ATP-hydrolysing); Drug combination; Enzyme; Carmustine; Etoposide; Enzyme inhibitor; Hodgkin disease; Malignant hemopathy; Lymphoma; Podophyllotoxine derivatives; Oxazaphosphinane derivatives; Alkylating agent; Chemotherapy; Cyclophosphamide; Nitrogen mustard; Combined treatment

One hundred nineteen patients with relapsed or refractory Hodgkin's disease (HD) received high-dose therapy followed by autologous hematopoietic progenitor cell transplantation. Three preparatory regimens, selected on the basis of prior therapy and pulmonary status, were employed. Twenty-six pa...